< Terug naar vorige pagina

Publicatie

Rapid-acting insulin analogues

Tijdschriftbijdrage - Tijdschriftartikel

Ondertitel:theory and best clinical practice in type 1 and type 2 diabetes
Since the discovery of insulin 100 years ago, insulin preparations have improved significantly. Starting from purified animal insulins, evolving to human insulins produced by genetically modified organisms, and ultimately to insulin analogues, all in an attempt to mimic physiological insulin action profiles seen in individuals without diabetes. Achieving strict glucose control without hypoglycaemia and preventing chronic complications of diabetes while preserving quality of life remains a challenging goal, but the advent of newer ultra-rapid-acting insulin analogues may enable intensive insulin therapy without being too disruptive to daily life. Ultra-rapid-acting insulin analogues can be administered shortly before meals and give better coverage of mealtime-induced glucose excursions than conventional insulin preparations. They also increase convenience with timing of bolus dosing. In this review, we focus on the progress that has been made in rapid-acting insulins. We summarize pharmacokinetic and pharmacodynamic data, clinical trial data supporting the use of these new formulations as part of a basal-bolus regimen and continuous subcutaneous insulin infusion, and provide a clinical perspective to help guide healthcare professionals when and for whom to use ultra-fast-acting insulins.
Tijdschrift: Diabetes, obesity & metabolism
ISSN: 1462-8902
Volume: 24
Pagina's: 63 - 74
Jaar van publicatie:2022
Trefwoorden:A1 Journal article
Toegankelijkheid:Closed